Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
UGT2B7 7364 CODEINE CHEMBL485 PharmGKB
UGT2B7 7364 ZIDOVUDINE CHEMBL129 PharmGKB
UGT2B7 7364 LORAZEPAM CHEMBL580 PharmGKB

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
UGT2B7 rs62298861 G codeine metabolism/PK no Post-mortem analysis of codeine-related deaths. No significant association between this variant and concentrations of codeine or morphine resulting from codeine metabolism. The G allele is also referred to in the paper as the UGT2B7*2 allele. Allele G is not associated with concentrations of codeine or morphine as compared to allele A. 24747667 1451206866
UGT2B7 rs7439366 CC valproic acid metabolism/PK not stated VPA plasma concentrations and VPA plasma concentrations adjusted by weight did not differ between the three genotypes. The authors classified the C>T variant as *2. Genotype CC is not associated with metabolism of valproic acid in children with Epilepsy. 23099353 1448634988
UGT2B7 rs10006452 C morphine metabolism/PK no Variant was potentially associated with morphine-6-glucuronide formation but lost significance following p-value correction. Allele C is not associated with metabolism of morphine in children as compared to allele T. 30920410 1451100980
UGT2B7 rs4235108 A fentanyl efficacy no There was no significant difference in PPLpost-PPLpre between the genotype groups. Allele A is not associated with response to fentanyl in people with Pain, Postoperative as compared to allele G. 28256933 1449715464
UGT2B7 rs28365063 AA carbamazepine metabolism/PK yes This association was only significant in the African American patients and not in Caucasian patients. Genotype AA is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to genotypes AG + GG. 23252947 981501889
UGT2B7 rs7439366 T morphine metabolism/PK no No rs numbers given. Variant described as H268Y. Allele T is not associated with concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide in people with Neoplasms as compared to allele C. 12185559 1450320917
UGT2B7 rs7439366 CC valproic acid "dosage","metabolism/PK" no Variant reported as UGT2B7 802T>C (rsID not reported, obtained from the UGT nomenclature website). Genotype CC is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CT + TT. 21806385 827812774
UGT2B7 rs7439366 TT oxycodone efficacy yes Referred to as C802T SNP in paper. The TT genotype was more frequent among patients who did not have an analgesic response to oxycodone than among patients who did respond. Genotype TT is associated with decreased response to oxycodone in people with Neoplasms and Pain as compared to genotype CC. 29502154 1449269466
UGT2B7 rs7668258 TT lamotrigine metabolism/PK yes This study was conducted in 100 patients -- 54 receiving monotherapy for lamotrigine, and 46 receiving combination therapy with carbamazepine, oxcarbazepine, valproic acid, phenytoin, phenobarbital, levetiracetam, topiramate, lacosamide, zonisamide, pregabalin, clonazepam, or clobazam. All patients were on stable therapy for at least 2 months. The significant difference in clearance was found between patients with the TT genotype and with the CC genotype, with clearance in patients with the CT genotype not being significantly different than in patients with the CC genotype. Genotype TT is associated with decreased clearance of lamotrigine in people with Epilepsy as compared to genotypes CC + CT. 27096250 1447983624
UGT2B7 rs7439366 C labetalol metabolism/PK no This SNP is not associated with PK of labetolol. Allele C is not associated with decreased metabolism of labetalol in healthy individuals as compared to allele T. 23090703 1183682327
UGT2B7 rs12233719 T fentanyl efficacy no No significant differences in postoperative fentanyl consumption or VAS scores at 24 hours post-surgery between genotypes. Data was not presented in the paper. Allele T is not associated with response to fentanyl in women with Pain, Postoperative as compared to allele G. 32401749 1451147943
UGT2B7 rs7438284 A lorazepam efficacy yes as part of the UGT2B7*2 haplotype. All healthy volunteers were also UGT2B15*2 homozygotes. Allele A is associated with increased response to lorazepam and valproic acid in healthy individuals as compared to allele T. 17687269 769164773
UGT2B7 rs7668258 CC efavirenz metabolism/PK no Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT. 26779253 1447680853
UGT2B7 rs28365062 G zidovudine metabolism/PK yes The G allele carriers had 57% lower mean AUC (P = .029, unpaired t test), 196% higher mean CL/F (P = .004, unpaired t test; Figure 3B), and 67% shorter mean elimination half-life (P = .030, unpaired t test) compared with A allele carriers Allele G is associated with increased metabolism of zidovudine as compared to allele A. 19628728 769259039
UGT2B7 rs28365062 GG valproic acid "dosage","metabolism/PK" no Variant described as UGT2B7 735A>G (rsID not reported, UGT nomenclature website used). Genotype GG is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AG. 21806385 827812768
UGT2B7 rs7668258 TT valproic acid "dosage","metabolism/PK" no Variant described as UGT2B7 -161C>T (rsID not reported, from the UGT nomenclature website). Genotype TT is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CC + CT. 21806385 827812759
UGT2B7 rs7439366 C carbamazepine "dosage","metabolism/PK" no and not associated with In concentration/dose ratio. Allele C is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T. 22188362 827824186
UGT2B7 rs7668282 CC + CT morphine metabolism/PK yes Presence of G allele associated with decreased glucuronidation of methadone to methadone-3-glucuronide and methadone-6-glucuronide. Please note that alleles have been complemented to the positive strand. Genotypes CC + CT is associated with decreased metabolism of morphine in people with Anemia, Sickle Cell as compared to genotype TT. 17724700 827807210
UGT2B7 rs7438135 G carbamazepine "dosage","metabolism/PK" no and not associated with In concentration/dose ratio. Allele G is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A. 22188362 827824191
UGT2B7 rs4235108 A fentanyl dosage no There was no significant difference in 24 hour fentanyl use between the genotype groups. Allele A is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele G. 28256933 1449715538
UGT2B7 rs11931604 C fentanyl efficacy no There was no significant difference in PPLpost-PPLpre between the genotype groups. Allele C is not associated with response to fentanyl in people with Pain, Postoperative as compared to allele T. 28256933 1449715478
UGT2B7 rs11931604 C fentanyl dosage no There was no significant difference in 24 hour fentanyl use between the genotype groups. Allele C is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele T. 28256933 1449715544
UGT2B7 rs7668258 T carbamazepine "dosage","metabolism/PK" no and not associated with In concentration/dose ratio. Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C. 22188362 827824178
UGT2B7 rs7668282 C fentanyl efficacy no There was no significant difference in PPLpost-PPLpre between the genotype groups. Allele C is not associated with response to fentanyl in people with Pain, Postoperative as compared to allele T. 28256933 1449715484
UGT2B7 rs28365062 G carbamazepine "dosage","metabolism/PK" no and not associated with In concentration/dose ratio. Allele G is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A. 22188362 827824182
UGT2B7 rs62296959 A morphine metabolism/PK no Variant was potentially associated with morphine-6-glucuronide formation but lost significance following p-value correction. Allele A is not associated with metabolism of morphine in children as compared to allele G. 30920410 1451100985
UGT2B7 rs7668282 C fentanyl dosage no There was no significant difference in 24 hour fentanyl use between the genotype groups. Allele C is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele T. 28256933 1449715558
UGT2B7 rs7439366 T lorazepam efficacy yes as part of the UGT2B7*2 haplotype. All healthy volunteers were also UGT2B15*2 homozygotes. Allele T is associated with increased response to lorazepam and valproic acid in healthy individuals as compared to allele C. 17687269 769164776
UGT2B7 rs7439366 CT methadone metabolism/PK yes Designated as UGT2B7*2A allele in paper. Patients with the CT genotype had higher peak plasma levels of (R)-methadone than patients with the CC or TT genotypes. A similar pattern was seen for (S)-methadone peak plasma levels however the association was not statistically significant. There was no effect of this variant on trough plasma levels of (R)- or (S)- methadone. Genotype CT is associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotypes CC + TT. 17178267 1449266505
UGT2B7 rs7439366 CC + CT morphine efficacy no Genotypes CC + CT are not associated with dose of morphine in people with Pain, Postoperative as compared to genotype TT. 16580900 1449244383
UGT2B7 rs7439366 CT morphine dosage no Genotype CT is not associated with dose of morphine in women with Pain, Postoperative as compared to genotype TT. 24703092 1449244619
UGT2B7 rs7439366 CT + TT morphine metabolism/PK yes Patients with the CT or TT genotypes had significantly lower plasma concentrations of morphine than patients with the CC genotype. Variant referred to in the paper as C802T. Genotypes CT + TT are associated with decreased concentrations of morphine in people with Neoplasms and Pain as compared to genotype CC. 31607718 1451124440
UGT2B7 rs7668258 CC lamotrigine "dosage","metabolism/PK" yes This SNP was presented as UGT2B7 -161 C>T. The lamotrigine clearance (CL/F) in patients carrying the T allele decreased by 18% as compared to patients with the CC genotype. Patients with the CC genotype may require a higher dose as compared to those carrying the T allele. Genotype CC is associated with increased clearance of lamotrigine as compared to genotypes CT + TT. 23263737 1183682134
UGT2B7 rs7668258 CC + CT valproic acid metabolism/PK yes as measured by dose adjusted plasma VPA. Genotypes CC + CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT. 27406852 1448261553
UGT2B7 rs7668258 CT valproic acid metabolism/PK yes In overall analysis CT genotype was associated with increased serum concentration of valproic acid as compared with the CC genotype (P = 0.01) as well as in the sub-group analysis in combination therapy (P = 0.04). Hoqever, the CT genotype also did not significantly affect the adjusted serum concentration as compared with CC genotype based on monotherapy data (P = 0.10). Genotype CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC. 29243113 1449169135
UGT2B7 rs7668258 TT valproic acid metabolism/PK yes 4 studies evaluated the association between CC & TT and adj. serum concentration of VPA. In overall analysis of 4 studies found no association with genotype and adj. serum concentration (P = 0.35). In subgroup analysis, the TT genotype was not significantly associated with serum concentration versus CC genotype in monotherapy (P =0.71) but was associated with increased concentrations based on combination therapy data (P = 0.002). No sub-group anayses were done by age. Genotype TT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC. 29243113 1449169125
UGT2B7 rs12233719 T carvedilol metabolism/PK yes When allele T is in combination with rs28365063 G allele, the combination of which is defined as UGT2B7*3 by the UGT Nomenclature Committee. As compared to the G allele combined with rs28365063 A allele (wild-type, or UGT2B7*1). In other words, UGT2B7*3 is associated with decreased oral clearance (CL/F) of carvedilol as compared to UGT2B7*1. Allele T is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to allele G. 17329852 982044299
UGT2B7 rs28365063 AA lamotrigine metabolism/PK yes This SNP was presented as UGT2B7 372 A>G. The lamotrigine clearance (CL/F) did not differ by genotype at this locus. Genotype AA is not associated with increased clearance of lamotrigine as compared to genotypes AG + GG. 23263737 1183682139
UGT2B7 rs7668258 CC lamotrigine metabolism/PK no The concentration was measured as lamotrigine trough concentration / dose normalized by body weight. Included patients had been on lamotrigine monotherapy for at least a month with complete medical records, had normal renal and hepatic functions, and had therapeutic drug monitoring with good compliance. Genotype CC is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype TT. 26213157 1448098996
UGT2B7 rs62298861 AA lamotrigine metabolism/PK no The concentration was measured as lamotrigine trough concentration / dose normalized by body weight. Included patients had been on lamotrigine monotherapy for at least a month with complete medical records, had normal renal and hepatic functions, and had therapeutic drug monitoring with good compliance. Genotype AA is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG. 26213157 1448098981
UGT2B7 rs7439366 T efavirenz metabolism/PK no No association was seen between this polymorphism and efavirenz plasma concentrations. Allele T is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele C. 23172109 1184473341
UGT2B7 rs28365062 G efavirenz metabolism/PK no No association was seen between this polymorphism and efavirenz plasma concentrations. Allele G is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele A. 23172109 1184473345
UGT2B7 rs12645107 A fentanyl dosage no There was no significant difference in 24 hour fentanyl use between the genotype groups. Allele A is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele G. 28256933 1449715576
UGT2B7 rs7439366 T fentanyl efficacy no No significant differences in postoperative fentanyl consumption or VAS scores at 24 hours post-surgery between genotypes. Allele T is not associated with response to fentanyl in women with Pain, Postoperative as compared to allele C. 32401749 1451147960
UGT2B7 rs7439366 T hydromorphone metabolism/PK no No significant difference in hydromorphone maximum plasma concentration (Cmax), area under the plasma concentration-time curve from 0 to 36 hours (AUC0-36h), AUCinfinity (AUCinf), time to maximum plasma concentration (tmax), or half-life time (t1/2) was seen between the UGT2B7 *1/*1 (CC), *1/*2 (CT) or *2/*2 (TT) genotypes. Additionally, no significant differences in Cmax, AUC0-36h or tmax were seen between the genotypes when considering hydromorphone-3-glucuronide. Allele T is not associated with metabolism of hydromorphone in healthy individuals as compared to allele C. 24706503 1296600073
UGT2B7 rs7438135 AA + AG morphine metabolism/PK yes In preterm newborns undergoing mechanical ventilation. Those who carried the A allele had lower morphine levels at 20 minutes post intubation, as compared to those with the GG genotype. A significant association was also seen when considering the morphine-3-glucuronide:morphine metabolic ratio (p=0.005). Genotypes AA + AG is associated with decreased concentrations of morphine in infants as compared to genotype GG. 25340733 1444934961
UGT2B7 rs7439366 TT efavirenz metabolism/PK no ON EFV-containing therapy for >7 days, absence of interacting drugs, no co-infection, drug intake 12 hrs (+/- 3 hrs) before blood draw, reported medication adherence above 90%. Receive 600 mg EFV once daily. Genotype TT is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CC + CT. 26774523 1447680448
UGT2B7 rs7668258 CT + TT lamotrigine metabolism/PK yes The authors reported that multiple variables impact steady-state concentration of lamotrigine in individuals with epilepsy. The SNP was associated with an increase in lamotrigine steady-state concentration. Genotypes CT + TT are associated with increased steady-state concentration of lamotrigine in people with Epilepsy as compared to genotype CC. 26790665 1447682974
UGT2B7 rs4455491 A morphine "dosage","efficacy" yes Variant is in complete linkage disequilibrium with rs11940220, rs11940316, rs7438135 and rs7668258 (identical allele and genotype frequencies were found at each locus). No significant association between the haplotype of these five variants and morphine glucuronidation was found. Allele A is not associated with metabolism of morphine in people with Pain, Postoperative as compared to allele G. 23686330 1449295831
UGT2B7 rs7439366 TT codeine dosage yes Women who delivered via C-section and were prescribed codeine for postpartum pain. Prescribed "Tylenol #3" (300 mg acetaminophen and 30 mg codeine). Some women also prescribed naproxen. Those with the TT genotype consumed a lower mean dose of codeine as compared to those with the CC genotype. This SNP was found to significantly predict mean dose intake in multiple linear regression. The authors go on to note that this variant was not predictive of mean dose intake by Asians, though it was predictive of mean dose intake by Caucasians; this may be due to differences in allele frequencies between the two ethnicities. Genotype TT is associated with decreased dose of codeine in women as compared to genotype CC. 25752520 1446902609
UGT2B7 rs28365063 GG lamotrigine metabolism/PK yes This study was conducted in 100 patients -- 54 receiving monotherapy for lamotrigine, and 46 receiving combination therapy with carbamazepine, oxcarbazepine, valproic acid, phenytoin, phenobarbital, levetiracetam, topiramate, lacosamide, zonisamide, pregabalin, clonazepam, or clobazam. All patients were on stable therapy for at least 2 months. Genotype GG is associated with increased clearance of lamotrigine in people with Epilepsy as compared to genotypes AA + AG. 27096250 1447983631
UGT2B7 rs7439366 C oxcarbazepine dosage no but did not remain significant after Bonferroni correction for multiple testing. Allele C is associated with increased dose of oxcarbazepine in people with Epilepsy as compared to allele T. 25823783 1447944945
UGT2B7 rs7439366 CC valproic acid dosage no Dosage did not differ between the three genotypes. The authors classified the C>T variant as *2. Genotype CC is not associated with dose of valproic acid in children with Epilepsy. 23099353 1448634981
UGT2B7 rs10028494 A fentanyl dosage no There was no significant difference in 24 hour fentanyl use between the genotype groups. Allele A is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele C. 28256933 1449715564
UGT2B7 rs28365063 G morphine metabolism/PK no Measures assessed were AUC, transit compartment rate constant, Volume of distribution, and clearance. Participants received 30 mg morphine and were sampled at time 0, 5, 10, 15, 30, 45, 60, 90, 120, and 150 min. Allele G is not associated with exposure to morphine in healthy individuals as compared to allele A. 28063968 1448531887
UGT2B7 rs7438135 G morphine metabolism/PK no Measures assessed were AUC, transit compartment rate constant, Volume of distribution, and clearance. Participants received 30 mg morphine and were sampled at time 0, 5, 10, 15, 30, 45, 60, 90, 120, and 150 min. Allele G is not associated with exposure to morphine in healthy individuals as compared to allele A. 28063968 1448531882
UGT2B7 UGT2B7 *2 buprenorphine efficacy yes *2 allele designation is based on the presence of rs7439366. However, the authors only refer to *1 and *2 alleles rather than the C or T alleles. Study carried out with postsurgery patients. Patients with *1/*2 and *2/*2 genotypes were grouped together. *1/*1 patients reported less severe pain at rest and coughing than carriers of the *2 allele. Genotype *2 is associated with decreased response to buprenorphine in people with Pain as compared to genotype *1. 24256307 1449154360
UGT2B7 rs7439366 CC oxcarbazepine metabolism/PK no Genotype CC is not associated with concentrations of oxcarbazepine in people with Epilepsy as compared to genotypes CT + TT. 28837897 1448998365
UGT2B7 rs7439366 C oxcarbazepine efficacy yes Allele C is associated with decreased response to oxcarbazepine in people with Epilepsy as compared to allele T. 28837897 1448998405
UGT2B7 rs7439366 C buprenorphine efficacy no The paper analyzes the analgesic effect of buprenorphine. Allele C is not associated with response to buprenorphine in people with Ischemia and Pain as compared to allele T. 26407542 1449147591
UGT2B7 rs12233719 GG valproic acid metabolism/PK no The GG genotype was associated with increased adj. serum concentration versus the GT genotype based on overall analysis (P < 0.00001). In subgroup of VPA monotherapy, adj. plasma VPA concentration was lower in TT genotype vs. GT (P < 0.00001) but was not significant in the combined therapy sub-group (P = 0.15). Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype GT. 29243113 1449169153
UGT2B7 rs7668258 C morphine "dosage","efficacy" no Haplotype of the four UGT2B7 variants studied in the paper was also not significantly associated with morphine dose requirements. Allele C is not associated with dose of morphine in people with Pain, Postoperative as compared to allele T. 26902643 1449295963
UGT2B7 rs7668282 C morphine "dosage","efficacy" no Haplotype of the four UGT2B7 variants studied in the paper was also not significantly associated with morphine dose requirements. Allele C is not associated with dose of morphine in people with Pain, Postoperative as compared to allele T. 26902643 1449295975
UGT2B7 rs73823859 G morphine "dosage","efficacy" no Haplotype of the four UGT2B7 variants studied in the paper was also not significantly associated with morphine dose requirements. Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A. 26902643 1449295969
UGT2B7 rs7438135 G morphine "dosage","efficacy" no Haplotype of the four UGT2B7 variants studied in the paper was also not significantly associated with morphine dose requirements. Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A. 26902643 1449295957
UGT2B7 rs7668258 T lamotrigine metabolism/PK no Allele T is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele C. 29791014 1449560369
UGT2B7 rs7439366 CT + TT oxycodone efficacy no Referred to as C802T SNP in paper. Genotypes CT + TT are not associated with dose of oxycodone in people with Neoplasms and Pain as compared to genotype CC. 29502154 1449269452
UGT2B7 rs7439366 CT oxycodone efficacy no Referred to as C802T SNP in paper. Genotype CT is not associated with response to oxycodone in people with Neoplasms and Pain as compared to genotype CC. 29502154 1449269459
UGT2B7 rs6851533 T fentanyl dosage no There was no significant difference in 24 hour fentanyl use between the genotype groups. Allele T is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele C. 28256933 1449715570
UGT2B7 rs7439366 T morphine dosage no Allele T is associated with increased concentrations of morphine or morphine-3-glucuronide in women with Pain, Postoperative as compared to allele C. 24703092 1449162960
UGT2B7 rs7439366 CC morphine dosage yes Genotype CC is associated with decreased dose of morphine in women with Pain, Postoperative as compared to genotype TT. 24703092 1449162934
UGT2B7 rs7439366 TT valproic acid metabolism/PK yes In two sub-group analyses the TT genotype was associated with dose adj. concentrations of valproic acid (VPA) but in opposite association with VPA concentration: 1) one study in combination therapy TT was associated with increased concentration vs. CC and 2) in two studies in a sub-group analysis of children on monotherapy the TT genotype was associated with decreased concentrations vs. the CC genotype. When evaluated overall there was no association. Genotype TT is associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC. 29243113 1449169100
UGT2B7 rs7439366 CT valproic acid metabolism/PK no The CT genotype was not associated with dose adj. concentrations of valproic acid (VPA) overall in 10 studies (P = 0.24). Sub-group analyses included monotherapy and combination therapy, nor by age. Genotype CT is not associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC. 29243113 1449169116
UGT2B7 rs6851533 C fentanyl efficacy no There was no significant difference in PPLpost-PPLpre between the genotype groups. Allele C is not associated with response to fentanyl in people with Pain, Postoperative as compared to allele T. 28256933 1449715490
UGT2B7 rs4296738 A fentanyl dosage no There was no significant difference in 24 hour fentanyl use between the genotype groups. Allele A is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele G. 28256933 1449715532
UGT2B7 rs4587017 TT fentanyl efficacy no There was a significant difference in PPLpost-PPLpre between the genotype groups. Genotype TT is associated with decreased response to fentanyl in people with Pain, Postoperative as compared to genotypes GG + GT. 28256933 1449715511
UGT2B7 rs4296738 A fentanyl efficacy no There was no significant difference in PPLpost-PPLpre between the genotype groups. Allele A is not associated with response to fentanyl in people with Pain, Postoperative as compared to allele G. 28256933 1449715471
UGT2B7 rs7439366 TT fentanyl efficacy yes There was a significant difference in PPLpost-PPLpre between the genotype groups. Genotype TT is associated with decreased response to fentanyl in people with Pain, Postoperative as compared to genotypes CC + CT. 28256933 1449715433
UGT2B7 rs7439366 TT fentanyl dosage no There was no significant difference in 24 hour fentanyl use between the genotype groups. Genotype TT is not associated with dose of fentanyl in people with Pain, Postoperative as compared to genotypes CC + CT. 28256933 1449715442
UGT2B7 rs12645107 A fentanyl efficacy no There was no significant difference in PPLpost-PPLpre between the genotype groups. Allele A is not associated with response to fentanyl in people with Pain, Postoperative as compared to allele G. 28256933 1449715496
UGT2B7 rs10028494 CC fentanyl efficacy yes There was a significant difference in PPLpost-PPLpre between the genotype groups. Genotype CC is associated with decreased response to fentanyl in people with Pain, Postoperative as compared to genotypes AA + AC. 28256933 1449715526
UGT2B7 rs12233719 GG valproic acid metabolism/PK yes Five studies evaluated the association between genotypes and adjusted serum concentration of overall analysis (P = 0.01). In the monotherapy subgroup, adjusted plasma VPA concentration was significantly lower in the TT genotype (P = 0.0006) but not in combination therapy subgroup (P = 0.58). Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT. 29243113 1449169145
UGT2B7 rs28365062 AA efavirenz metabolism/PK no ON EFV-containing therapy for >7 days, absence of interacting drugs, no co-infection, drug intake 12 hrs (+/- 3 hrs) before blood draw, reported medication adherence above 90%. Receive 600 mg EFV once daily. Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG. 26774523 1447680442
UGT2B7 rs28365063 G carvedilol metabolism/PK yes When allele G is in combination with rs12233719 T allele, the combination of which is defined as UGT2B7*3 by the UGT Nomenclature Committee. As compared to the A allele combined with rs12233719 G allele (wild-type, or UGT2B7*1). In other words, UGT2B7*3 is associated with decreased oral clearance (CL/F) of carvedilol as compared to UGT2B7*1. Allele G is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to allele A. 17329852 982044307
UGT2B7 rs28365062 GG efavirenz metabolism/PK yes As measured by increased plasma concentrations in patients with the GG genotype compared to the other genotypes (allele model was not statistically significant, perhaps due to low numbers of patients with the GG genotype). *Note: All participants were CYP2B6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC).* Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotypes AA + AG. 24729586 1184467530
UGT2B7 rs61361928 TT ticagrelor metabolism/PK yes Part of a GWAS study with replication cohort. This study did not find changes in primary coronary event outcomes on ticagrelor, but did find differences in AUC of ticagrelor metabolite ARC (AR-C124910XX). Genotype TT is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to genotype CT. 25935875 1447987289
UGT2B7 rs73823859 G mycophenolic acid metabolism/PK no A total of 166 plasma concentrations were available for population modeling. Mycophenolic acid PK was described as a time lagged two compartment model with first-order absorption and elimination and kinetics in accordance with sustained drug release (flip-flop). During covariate model building using step-wise covariate modeling (SCM) several covariates, including multiple genetic polymorphisms, produced a significant decrease in objective function value (OFV). Only rs2306283 and rs3832043 remained significant in the full covariate model, which included effect size. The two polymorphisms also remained significant in the backwards elimination model. Allele G is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele A. 25163792 1184755654
UGT2B7 rs4587017 G fentanyl dosage no There was no significant difference in 24 hour fentanyl use between the genotype groups. Allele G is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele T. 28256933 1449715552
UGT2B7 rs7662029 G mycophenolic acid metabolism/PK yes this was significant in additive and dominant model. Allele G is associated with increased dose-adjusted trough concentrations of mycophenolic acid in people with Kidney Transplantation as compared to allele A. 30345879 1450112752
UGT2B7 rs28375964 T morphine metabolism/PK no Variant was potentially associated with morphine-6-glucuronide formation but lost significance following p-value correction. Allele T is not associated with metabolism of morphine in children as compared to allele C. 30920410 1451100940
UGT2B7 rs12233719 T morphine dosage no No significant difference in loading dose or cumulative dose of morphine between genotype groups. Variant referred to in the paper as G221T. Allele T is not associated with dose of morphine in people with Neoplasms and Pain as compared to allele G. 31607718 1451124380
UGT2B7 rs7439366 C morphine dosage no No significant difference in loading dose or cumulative dose of morphine between genotype groups. Variant referred to in the paper as C802T. Allele C is not associated with dose of morphine in people with Neoplasms and Pain as compared to allele T. 31607718 1451124322
UGT2B7 rs7439366 CT + TT morphine efficacy yes Patients with the CT or TT genotypes had significantly higher VAS pain scores than patients with the CC genotype. Variant referred to in the paper as C802T. Genotypes CT + TT are associated with decreased response to morphine in people with Neoplasms and Pain as compared to genotype CC. 31607718 1451124400
UGT2B7 rs12233719 T morphine efficacy no No significant difference in VAS pain scores between genotype groups. Variant referred to in the paper as G221T. Allele T is not associated with response to morphine in people with Neoplasms and Pain as compared to allele G. 31607718 1451124460
UGT2B7 rs12233719 T morphine metabolism/PK no No significant difference in plasma concentrations of morphine between genotype groups. Variant referred to in the paper as G221T. Allele T is not associated with concentrations of morphine in people with Neoplasms and Pain as compared to allele G. 31607718 1451124467